Neurological Biomarkers Market Report 2026

Neurological Biomarkers Market Overview

• Neurological Biomarkers market size has reached to $11.92 billion in 2025 • Expected to grow to $22.82 billion in 2030 at a compound annual growth rate (CAGR) of 14% • Growth Driver: Rising Prevalence Of Neurological Diseases Fuels Momentum In Neurological Biomarker Market • Market Trend: Revolutionizing Alzheimer's Disease Diagnosis And Patient Evaluation With Biomarker Blood Test • North America was the largest region in 2025.

What Is Covered Under Neurological Biomarkers Market?

A neurological biomarker is a substance that provides objective and quantifiable information about the presence, progression, or characteristics of a neurological disorder or condition. They are used in clinical practice during drug development. The main products of neurological biomarkers are proteomics biomarkers, genomics biomarkers, metabolomics biomarkers, imaging biomarkers, and others. Proteomics biomarkers refer to types of biomarkers that have specific proteins or patterns of proteins that can be identified and monitored by analyzing the proteins in the body fluid. They are used for various applications such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, schizophrenia, depression, multiple sclerosis, and spinal muscular atrophy by hospital laboratories, clinical diagnostic centers, research organizations, and others.

What Is The Neurological Biomarkers Market Growth Forecast?

The neurological biomarkers market size is expected to see rapid growth in the next few years. It will grow to $22.82 billion in 2030 at a compound annual growth rate (CAGR) of 14.0%. The growth in the forecast period can be attributed to expanding use of biomarker-based personalized medicine, rising demand for metabolomics biomarkers, increasing investment in cns drug development, development of next-generation diagnostic platforms, growing application of biomarker-driven disease monitoring. Major trends in the forecast period include growing use of biomarkers in early neurological diagnosis, increasing adoption of proteomic and genomic biomarkers, expansion of imaging biomarkers in cns disorder evaluation, rising demand for biomarkers in drug development pipelines, growing clinical focus on neurodegenerative disease biomarker testing.

What Is The Driver Of The Neurological Biomarkers Market?

The increasing prevalence of neurological diseases is expected to propel the growth of the neurological biomarker market going forward. Neurological illnesses affect the brain, spinal cord, and all of the body's other nerves. Parkinson's disease is a neurodegenerative disorder affecting the neurological system and the areas of the body that are under the control of the nerves. Neurological biomarkers help provide an early diagnosis of Parkinson's disease using pathological, biochemical, and genetic testing. For instance, in October 2023, according to the World Federation of Neurology, a UK-based charity, reflecting an accelerating global health burden, neurological disorders now represent the second-leading cause of death and the primary cause of disability worldwide, with more than 40 percent of the global population affected in 2023 and the number of individuals living with brain disease projected to nearly double by 2050. Therefore, the increasing prevalence of neurological diseases is driving the growth of the neurological biomarker industry.

Key Players In The Global Neurological Biomarkers Market

Major companies operating in the neurological biomarkers market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Thermos Fisher Scientific Inc., AstraZeneca Plc, Abbott Laboratories, Boehringer Ingelheim International GmbH, Becton Dickinson and Company, Agilent Technologies Inc., Grifols S.A., Eisai Co. Ltd., PerkinElmer Inc., Illumina Inc., Shimadzu Corporation, Waters Corporation, Bio-Rad Laboratories Inc., Mallinckrodt Plc, Qiagen N.V., Luminex Corporation, Siemens Healthineers, Olink Proteomics, Meso Scale Diagnostics, Quanterix Corp., Fujirebio, Cisbio Bioassays SAS, NeuroVision Imaging, Proteome Sciences Plc, Acumen Pharmaceuticals.

Global Neurological Biomarkers Market Trends and Insights

Major companies operating in the neurological biomarkers market are developing new products such as advanced biomarker blood tests to gain a competitive edge in the market. Biomarker blood tests involve the analysis of specific molecules or indicators in the blood that provide information about a biological condition, disease, or physiological process. For instance, in July 2023, Quanterix Corporation, a US-based company that specializes in the development and commercialization of ultra-sensitive digital immunoassay platforms launched the LucentAD biomarker blood test. The LucentAD test is intended to assist medical professionals in evaluating patients who have cognitive symptoms that align with preliminary indications of alzheimer's disease. The test quantifies levels of p-Tau 181, which has been demonstrated to be a biomarker of the pathophysiology of alzheimer's disease (AD). When an adult is being tested for AD 1 and has cognitive impairment, the LucentAD test findings are meant to be utilized as a diagnostic tool. The test is not meant to be used as a stand-alone screening or diagnostic assay and it must be used in conjunction with other diagnostic tools.

What Are Latest Mergers And Acquisitions In The Neurological Biomarkers Market?

In April 2024, GE HealthCare, a US-based medical technology company, acquired a MIM Software Inc. for an undisclosed amount. GE HealthCare aims to enhance precision care by integrating advanced imaging analytics and streamlining workflows, ultimately improving patient outcomes and clinician efficiency. This strategic move positions GE HealthCare to deliver more personalized treatment solutions across various medical specialties. MIM Software Inc., a US-based medical imaging software company, provides advanced imaging solutions that can enhance the identification and analysis of neurological biomarkers.

What Defines the Neurological Biomarkers Market?

The neurological biomarker market consists of sales of genetic testing kits, electroencephalography (EEG) devices, and biomarker assay kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Neurological Biomarkers Market Report 2026?

The neurological biomarkers market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the neurological biomarkers industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.